Mirko Farina
YOU?
Author Swipe
View article: Endoscopic endonasal transsphenoidal surgery in children: widening the spectrum of oncological indications in the pediatric age group
Endoscopic endonasal transsphenoidal surgery in children: widening the spectrum of oncological indications in the pediatric age group Open
View article: Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50
Development of a Simplified Geriatric Score-4 (SGS-4) to Predict Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation in Patients Aged over 50 Open
Background: The Comprehensive Geriatric Assessment (CGA) has proven to be a valuable tool for providing a more comprehensive health evaluation of allogeneic stem cell transplantation (allo-SCT) recipients. Methods: We prospectively develop…
View article: Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles
Assessment of Chronic Myeloid Leukaemia In Vitro Models Variability: Insights Into Extracellular Vesicles Open
Chronic Myeloid Leukaemia is driven by the BCR::ABL1 fusion gene. Although Tyrosine Kinase Inhibitors have significantly improved patient outcomes, drug resistance and disease persistence remain challenges, highlighting the need for effect…
View article: Artificial Intelligence-Driven Personalization in Breast Cancer Screening: From Population Models to Individualized Protocols
Artificial Intelligence-Driven Personalization in Breast Cancer Screening: From Population Models to Individualized Protocols Open
Conventional breast cancer screening programs are predominantly age-based, applying uniform intervals and modalities across broad populations. While this model has reduced mortality, it entails harms—including overdiagnosis, false positive…
View article: Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib
Revised “iRR6” model in intermediate‐1 risk myelofibrosis patients treated with ruxolitinib Open
Background The response to ruxolitinib after 6 months (RR6) model allows early identification of ruxolitinib‐treated myelofibrosis (MF) patients with poorer overall survival (OS); however, it is less applicable to lower‐risk patients. Meth…
View article: Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis
Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis Open
High-grade B-cell lymphomas [HGBL, including double-hit/triple-hit (HGBL-DH/TH) and HGBL not otherwise specified (HGBL-NOS)] have a poor prognosis upon failure of first-line therapy. Anti-CD19 chimeric antigen receptor (CAR) T-cells for th…
View article: A case of severe gastrointestinal toxicity after allogeneic hematopoietic stem cell transplantation: can we improve the evaluation of the “gut fitness“ ?
A case of severe gastrointestinal toxicity after allogeneic hematopoietic stem cell transplantation: can we improve the evaluation of the “gut fitness“ ? Open
View article: The 2024 Three‐Strata Baseline Anemia Definition of the Revised <scp>IWG</scp>‐<scp>ELN</scp> Criteria Dissects Survival in Ruxolitinib‐Treated Myelofibrosis Patients
The 2024 Three‐Strata Baseline Anemia Definition of the Revised <span>IWG</span>‐<span>ELN</span> Criteria Dissects Survival in Ruxolitinib‐Treated Myelofibrosis Patients Open
View article: 350 | PATIENTS WITH RELAPSED/REFRACTORY PMBCL HAVE BETTER SURVIVAL WHEN THE SALVAGE STRATEGY INCLUDES CAR T‐CELLS: AN ANALYSIS OF THE REPRIME‐FIL AND THE CART‐SIE STUDIES
350 | PATIENTS WITH RELAPSED/REFRACTORY PMBCL HAVE BETTER SURVIVAL WHEN THE SALVAGE STRATEGY INCLUDES CAR T‐CELLS: AN ANALYSIS OF THE REPRIME‐FIL AND THE CART‐SIE STUDIES Open
View article: 447 | POLATUZUMAB‐CONTAINING REGIMENS AS BRIDGE TO CAR‐T: INSIGHTS FROM THE ITALIAN CAR T‐SIE STUDY
447 | POLATUZUMAB‐CONTAINING REGIMENS AS BRIDGE TO CAR‐T: INSIGHTS FROM THE ITALIAN CAR T‐SIE STUDY Open
View article: CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE study Open
CAR T expansion has been linked to anti-tumor response in relapsed/refractory large B-cell lymphoma both in clinical trials and smaller real-world studies. Here, we present the largest multicenter real-world analysis to date, evaluating 26…
View article: Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea Open
The European LeukemiaNet recently proposed specific Clinical Signs and Symptoms (CSSs) that may trigger cytoreduction in patients with polycythemia vera (PV) at low thrombotic risk (LR). To evaluate the impact of CSSs on the thrombotic ris…
View article: Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study Open
View article: Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending?
Intensive Chemotherapy Versus Venetoclax-Based Regimens in Elderly Patients with Acute Myeloid Leukemia: Is the Chemotherapy Era Ending? Open
Background: Acute myeloid leukemia (AML) primarily affects older adults and is associated with poor prognosis, particularly in patients aged ≥ 60 years with comorbidities and adverse disease characteristics. Standard intensive chemotherapy…
View article: Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea
Impact of ELN clinical signs and symptoms on the thrombotic risk in Polycythemia Vera patients treated with front-line hydroxyurea Open
The European LeukemiaNet recently proposed specific Clinical Signs and Symptoms (CSSs) that should be considered to trigger cytoreduction in patients with polycythemia vera (PV) at low risk (LR) according to conventional criteria (age<60 y…
View article: Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent Open
Chronic Myeloid Leukemia (CML) is characterized by the BCR::ABL1 fusion gene, driving uncontrolled myeloid cell proliferation. Furthermore, metabolic dysregulation contributes to disease progression. Despite the efficacy of tyrosine kinase…
View article: Neuro-toxoplasmosis in haploidentical haematopoietic stem cell transplant
Neuro-toxoplasmosis in haploidentical haematopoietic stem cell transplant Open
Allogeneic haematopoietic stem cell transplant is a routine procedure for several haematological disorders though infections are the main cause of morbidity and mortality. Rare infections, such as protozoan reactivations, can be life-threa…
View article: Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study
Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study Open
View article: Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant Recipient
Isolated Cerebral Myeloid Sarcoma in an Allogeneic Stem Cell Transplant Recipient Open
View article: Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy Open
View article: Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis
Cytopenias and Large Splenomegaly are Main Drivers of Poor Outcome after Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis Open
View article: Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study
Digital PCR (dPCR) is able to anticipate the achievement of stable deep molecular response in adult chronic myeloid leukemia patients: results of the DEMONSTRATE study Open
View article: CEREBRAL RADIONECROSIS IN PATIENTS IRRADIATED FOR CAVUM CANCER: RETROSPECTIVE STUDY OF 15 CASES
CEREBRAL RADIONECROSIS IN PATIENTS IRRADIATED FOR CAVUM CANCER: RETROSPECTIVE STUDY OF 15 CASES Open
Introduction: Cerebral radionecrosis is a rare but a serious complication induced by radiotherapy of the nasopharyngeal cancer. Since nasopharyngeal cancer is common to have skull base infiltration, radiation fields cover inevitably the te…
View article: In Vitro Biocompatibility Assessment of Bioengineered PLA-Hydrogel Core–Shell Scaffolds with Mesenchymal Stromal Cells for Bone Regeneration
In Vitro Biocompatibility Assessment of Bioengineered PLA-Hydrogel Core–Shell Scaffolds with Mesenchymal Stromal Cells for Bone Regeneration Open
Human mesenchymal stromal cells (hMSCs), whether used alone or together with three-dimensional scaffolds, are the best-studied postnatal stem cells in regenerative medicine. In this study, innovative composite scaffolds consisting of a cor…
View article: Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study
Clinical outcomes of ruxolitinib treatment in 595 intermediate‐1 risk patients with myelofibrosis: The RUX‐MF Real‐World Study Open
Background Ruxolitinib (RUX) is a JAK1/2 inhibitor approved for the therapy of myelofibrosis (MF) based on clinical trials including only intermediate2‐high risk (INT2/HIGH) patients. However, RUX is commonly used in intermediate‐1 (INT1) …
View article: Secondary primary malignancies after <scp>CD‐19</scp> directed <scp>CAR</scp>‐T‐cell therapy in lymphomas: A report from the Italian <scp>CART</scp>‐<scp>SIE</scp> study
Secondary primary malignancies after <span>CD‐19</span> directed <span>CAR</span>‐T‐cell therapy in lymphomas: A report from the Italian <span>CART</span>‐<span>SIE</span> study Open
Summary Secondary primary malignancies (SPM) have been reported after anti‐BCMA or anti‐CD19 chimeric antigen receptor (CAR)‐T‐cell therapies. While the cytotoxic effect of antecedent therapies, including chemotherapy and radiotherapy, has…
View article: Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib
Validation and molecular integration of the RR6 model to predict survival after 6 months of therapy with ruxolitinib Open
In this retrospective, single-center study, we aimed to validate the RR6 model, compare its performance with currently validated prognostic models, and explore the independent contribution of genetic factors. The study was conducted in acc…
View article: <i>BCR::ABL1</i> digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis
<i>BCR::ABL1</i> digital PCR for treatment‐free remission prediction in chronic myeloid leukemia patients: An individual participant data meta‐analysis Open
Approximately half of chronic phase (CP) CML patients in a stable deep molecular response (DMR; MR4.0; BCR::ABL1<0.01% on the International Scale [IS]) can safely and durably cease their therapy, entering a treatment-free remission (TFR).1…
View article: Supplementary Table S2 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Supplementary Table S2 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms Open
ATAC-Seq analysis - MPN vs. TAM
View article: Supplementary Table S3 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms
Supplementary Table S3 from Jak2<sup>V617F</sup> Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms Open
RNA-Seq analysis - MPN vs. RUX